Posted on 23/12/2009 in Pharmaceutical Company Product News Ferring has announced the positive outcome of a clinical study into its prostate cancer treatment FIRMAGON (degarelix).
The results showed that those patients receiving FIRMAGON have a significantly lower chance of prostate-specific-antigen (PSA) recurrence compared with those taking existing treatment leuprolide.
Furthermore, an analysis which was published in the British Journal of Urology suggested that FIRMAGON offers better control of serum alkaline phosphatase than leuprolide.
FIRMAGON is a gonadotropin-releasing hormone antagonist approved in the EU and the US.
Professor Bertrand Tombal, chairman of urology at Cliniques Universitaires Saint-Luc, commented: "These data add to the evidence demonstrating that FIRMAGON offers an important treatment choice for men with prostate cancer."
Earlier this year, Ferring announced the launch of its Fertility Media Award, an accolade it created to recognise outstanding levels of reporting in medical and consumer media about treatments that can help couples who struggle to conceive naturally. Other news stories from 23/12/2009
Read more in the Zenopa News Archive
How this news is generated
|
